Price to Earnings (P/E)
since 2005
Paying user area
Try for free
Celgene Corp. pages available for free this week:
- Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Liquidity Ratios
- Analysis of Solvency Ratios
- Common Stock Valuation Ratios
- Enterprise Value to EBITDA (EV/EBITDA)
- Price to FCFE (P/FCFE)
- Selected Financial Data since 2005
- Price to Sales (P/S) since 2005
- Analysis of Debt
- Aggregate Accruals
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Celgene Corp. for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Calculation
Celgene Corp., P/E, long-term trends, calculation
| P/E | = | Share price1, 2, 3 | ÷ | Earnings per share1 (EPS) | EPS1 | = | Net income (loss) attributable to Celgene1 (in millions) |
÷ | No. shares of common stock outstanding2 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 26, 2019 | = | ÷ | = | ÷ | |||||||
| Feb 7, 2018 | = | ÷ | = | ÷ | |||||||
| Feb 10, 2017 | = | ÷ | = | ÷ | |||||||
| Feb 11, 2016 | = | ÷ | = | ÷ | |||||||
| Feb 20, 2015 | = | ÷ | = | ÷ | |||||||
| Feb 13, 2014 | = | ÷ | = | ÷ | |||||||
| Feb 15, 2013 | = | ÷ | = | ÷ | |||||||
| Feb 22, 2012 | = | ÷ | = | ÷ | |||||||
| Mar 1, 2011 | = | ÷ | = | ÷ | |||||||
| Feb 18, 2010 | = | ÷ | = | ÷ | |||||||
| Feb 17, 2009 | = | ÷ | = | ÷ | |||||||
| Feb 20, 2008 | = | ÷ | = | ÷ | |||||||
| Feb 27, 2007 | = | ÷ | = | ÷ | |||||||
| Mar 15, 2006 | = | ÷ | = | ÷ |
Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
1 US$
2 Data adjusted for splits and stock dividends.
3 Closing price as at the filing date of Celgene Corp. Annual Report.
- Share Price
- The share price demonstrated an overall upward trend from 2006 through 2019, beginning at $20.50 and reaching a peak of $123.43 in 2015. Following this peak, the price experienced some volatility, declining to $89.71 by 2019. Notable increases occurred between 2011 and 2015, with the share price more than quadrupling in that period, suggesting significant market optimism or positive company developments during those years.
- Earnings Per Share (EPS)
- EPS showed considerable fluctuations over the years. Starting at $0.09 in 2006, EPS experienced a sharp decline in 2009, dropping to a negative value of -$1.67, indicating a period of losses. From 2010 onward, EPS recovered steadily, exhibiting consistent growth each year and reaching $5.76 by 2019. This recovery and growth in EPS imply improving profitability and operational performance over the latter part of the time span.
- Price-to-Earnings (P/E) Ratio
- The P/E ratio showed significant variability, influenced by changes in both share price and earnings. Early in the period (2006-2008), the P/E ratio was exceptionally high, ranging from 97.86 to over 291, reflecting relatively low earnings and/or elevated share prices. The ratio was not calculable in 2009 due to negative EPS. After 2009, the P/E ratio generally declined, from 35.45 in 2010 to 15.57 in 2019, indicating earnings growth outpacing share price appreciation and potentially a market revaluation towards a fairer price relative to earnings. However, spikes in the P/E ratio in the early 2010s (above 40) suggest occasional periods where stock price gains were disproportionate to earnings growth.
- Overall Analysis
- The financial metrics portray a company that experienced a challenging phase in 2009, as indicated by negative earnings and an inability to compute P/E ratio, reflecting operational difficulties or extraordinary events. Subsequent years highlight a robust recovery with marked improvements in profitability as expressed by rising EPS. Share price trends generally correspond with these earnings improvements, though share price volatility and P/E fluctuations suggest periods of market uncertainty or changing investor expectations. By 2019, the combination of higher EPS and a lower P/E ratio suggests that the stock was potentially more reasonably valued relative to earnings compared to earlier years.
Comparison to Competitors
Celgene Corp., P/E, long-term trends, comparison to competitors
| Celgene Corp. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 26, 2019 | |||||||||||||
| Feb 7, 2018 | |||||||||||||
| Feb 10, 2017 | |||||||||||||
| Feb 11, 2016 | |||||||||||||
| Feb 20, 2015 | |||||||||||||
| Feb 13, 2014 | |||||||||||||
| Feb 15, 2013 | |||||||||||||
| Feb 22, 2012 | |||||||||||||
| Mar 1, 2011 | |||||||||||||
| Feb 18, 2010 | |||||||||||||
| Feb 17, 2009 | |||||||||||||
| Feb 20, 2008 | |||||||||||||
| Feb 27, 2007 | |||||||||||||
| Mar 15, 2006 |
Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
Celgene Corp., P/E, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
| Celgene Corp. | Pharmaceuticals, Biotechnology & Life Sciences | |
|---|---|---|
| Feb 26, 2019 | ||
| Feb 7, 2018 | ||
| Feb 10, 2017 | ||
| Feb 11, 2016 | ||
| Feb 20, 2015 | ||
| Feb 13, 2014 | ||
| Feb 15, 2013 | ||
| Feb 22, 2012 | ||
| Mar 1, 2011 | ||
| Feb 18, 2010 | ||
| Feb 17, 2009 | ||
| Feb 20, 2008 | ||
| Feb 27, 2007 | ||
| Mar 15, 2006 |
Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Industry (Health Care)
Celgene Corp., P/E, long-term trends, comparison to industry (health care)
| Celgene Corp. | Health Care | |
|---|---|---|
| Feb 26, 2019 | ||
| Feb 7, 2018 | ||
| Feb 10, 2017 | ||
| Feb 11, 2016 | ||
| Feb 20, 2015 | ||
| Feb 13, 2014 | ||
| Feb 15, 2013 | ||
| Feb 22, 2012 | ||
| Mar 1, 2011 | ||
| Feb 18, 2010 | ||
| Feb 17, 2009 | ||
| Feb 20, 2008 | ||
| Feb 27, 2007 | ||
| Mar 15, 2006 |
Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).